CLDN6 and neoplasm: The CARVac strategy demonstrated that LNP-mediated delivery of the CLDN6 antigen to antigen-presenting cells (APCs) in the lymphoid compartments of mice could promote robust expansion of CLDN6 CAR-T cells and improved anti-tumor efficacy (76).